ARTICLE | Clinical News
Tysabri natalizumab: Phase III data
July 4, 2005 7:00 AM UTC
Data from the double-blind, placebo-controlled, international Phase III ENCORE trial of Tysabri natalizumab in 510 patients showed that Tysabri met the primary and all secondary endpoints. There were ...